Micafungin Dosing for Invasive Candidiasis in Adults
For invasive candidiasis including candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses in adults, use micafungin 100 mg IV once daily. This is the FDA-approved dose and is supported by both the 2025 global guideline and 2016 IDSA guideline 1.
Standard Dosing Recommendations
The FDA label clearly specifies 1:
- Candidemia and invasive candidiasis: 100 mg once daily
- Esophageal candidiasis: 150 mg once daily (if treating this specific manifestation)
- Prophylaxis in HSCT recipients: 50 mg once daily
Treatment duration for successfully treated candidemia and invasive candidiasis averaged 15 days (range 10-47 days) in clinical trials, and should continue for at least 2 weeks after documented clearance of Candida from bloodstream and resolution of clinical signs 2.
Critical Considerations for Dose Escalation
When Standard Dosing May Be Insufficient
In critically ill ICU patients, particularly those with high SOFA scores or elevated liver enzymes (ALT >120 U/L), consider higher doses up to 150-200 mg daily 3, 4. Micafungin clearance is 30-51% higher in ICU patients compared to non-ICU patients, potentially leading to subtherapeutic levels 3.
Species-Specific Considerations
The standard 100 mg dose achieves adequate target attainment for:
- C. albicans with MIC ≤0.016 mg/L (most isolates)
- C. tropicalis may require 200 mg/day for optimal coverage 3, 5
- C. glabrata may require 200-250 mg/day 3
- C. parapsilosis shows inherently higher MICs; efficacy improves with doses ≥100 mg/day but may still be suboptimal 5, 4
- C. krusei may not achieve adequate target attainment even with higher doses 3
Real-world data demonstrates that doses ≥100 mg/day achieve 87.5% efficacy compared to only 40% with 50 mg/day 5.
Practical Dosing Algorithm
Start with 100 mg IV once daily for all adult patients with invasive candidiasis 1
Escalate to 150-200 mg daily if:
Consider doses up to 300-400 mg daily in extreme cases:
Duration: Minimum 14 days from documented blood culture clearance and clinical improvement 2, 7. Treatment for ≥14 days showed significantly better outcomes (83.3% success) compared to shorter courses 7.
Safety Profile with Higher Doses
High-dose micafungin (200-400 mg daily) has been shown to be safe with minimal hepatotoxicity 6. In a study of patients receiving ≥200 mg daily, transaminases remained stable, though alkaline phosphatase showed a trend toward increase 6. Only 3 patients discontinued treatment due to adverse events in a large real-world study 7.
Essential Adjunctive Measures
- Remove central venous catheters as early as safely possible - this is strongly recommended and impacts outcomes 8, 2
- Obtain ophthalmologic examination to rule out endophthalmitis 2
- Consider therapeutic drug monitoring if available, targeting trough concentrations >1 mg/L, especially in critically ill patients with altered volume of distribution, hypoalbuminemia, or extracorporeal circuits 8
Common Pitfalls to Avoid
- Do not use 50 mg daily for invasive candidiasis - this prophylaxis dose is inadequate for treatment 5
- Do not assume all Candida species respond equally - obtain species identification and susceptibility testing when possible
- Do not stop therapy prematurely - outcomes significantly improve with ≥14 days of treatment 7
- Do not mix or co-infuse micafungin with other medications - it precipitates with many common drugs 1